Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 121 results:
Author [ Title(Desc)] Type Year
Filters: Author is van Staa, T. P.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
B. van Bodegraven, Palin, V., Mistry, C., Sperrin, M., White, A., Welfare, W., Ashcroft, D. M., and van Staa, T. P., “Infection-related complications after common infection in association with new antibiotic prescribing in primary care: retrospective cohort study using linked electronic health records”, BMJ Open, vol. 11, p. e041218, 2021.
A. M. Gallagher, Rietbrock, S., Plumb, J., and van Staa, T. P., “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?”, J Thromb Haemost, vol. 6, pp. 1500-6, 2008.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., Auvinen, A., van Staa, T. P., de Vries, F., and De Bruin, M. L., “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
L
D. E. Robinson, van Staa, T. P., Dennison, E. M., Cooper, C., and Dixon, W. G., “The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study”, Bone, vol. 117, pp. 83-90, 2018.
I. Wilting, de Vries, F., Thio, B. M., Cooper, C., Heerdink, E. R., Leufkens, H. G., Nolen, W. A., Egberts, A. C., and van Staa, T. P., “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
F. de Vries, Setakis, E., Zhang, B., and van Staa, T. P., “Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD”, Eur Respir J, vol. 36, pp. 494-502, 2010.
R. W. Atkinson, Carey, I. M., Kent, A. J., van Staa, T. P., Anderson, H. R., and Cook, D. G., “Long-term exposure to outdoor air pollution and incidence of cardiovascular diseases”, Epidemiology, vol. 24, pp. 44-53, 2013.
R. W. Atkinson, Carey, I. M., Kent, A. J., van Staa, T. P., Anderson, H. R., and Cook, D. G., “Long-term exposure to outdoor air pollution and the incidence of chronic obstructive pulmonary disease in a national English cohort”, Occup Environ Med, vol. 72, pp. 42-8, 2015.
R. M. Joseph, Ray, D. W., Keevil, B., van Staa, T. P., and Dixon, W. G., “Low salivary cortisol levels in patients with rheumatoid arthritis exposed to oral glucocorticoids: a cross-sectional study set within UK electronic health records”, RMD Open, vol. 4, p. e000700, 2018.
N
T. P. van Staa, Boulton, F., Cooper, C., Hagenbeek, A., Inskip, H., and Leufkens, H. G., “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
O
T. P. van Staa, Dyson, L., McCann, G., Padmanabhan, S., Belatri, R., Goldacre, B., Cassell, J., Pirmohamed, M., Torgerson, D., Ronaldson, S., Adamson, J., Taweel, A., Delaney, B., Mahmood, S., Baracaia, S., Round, T., Fox, R., Hunter, T., Gulliford, M., and Smeeth, L., “The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials”, Health Technol Assess, vol. 18, pp. 1-146, 2014.
K. Wing, Bhaskaran, K., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., and Douglas, I., “Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury”, BMJ Open, vol. 6, p. e012102, 2016.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
P
B. Zhang, de Vries, F., Setakis, E., and van Staa, T. P., “The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database”, J Hypertens, vol. 27, pp. 1485-92, 2009.
H. J. I. De Jong, Tervaert, J. W. Cohen, Lalmohamed, A., de Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., and van Staa, T. P., “Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink”, PLoS One, vol. 13, p. e0193297, 2018.
H. J. I. De Jong, van Staa, T. P., Lalmohamed, A., de Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., and Tervaert, J. W. Cohen, “Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study”, Ann Rheum Dis, vol. 76, pp. 1723-1730, 2017.
H. A. van den Ham, Klungel, O. H., Leufkens, H. G., and van Staa, T. P., “The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation”, J Thromb Haemost, vol. 11, pp. 107-15, 2013.
A. Lalmohamed, Macgregor, A. J., de Vries, F., Leufkens, H. G., and van Staa, T. P., “Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England”, PLoS One, vol. 8, p. e65891, 2013.
A. Dregan, van Staa, T. P., McDermott, L., McCann, G., Ashworth, M., Charlton, J., Wolfe, C. D., Rudd, A., Yardley, L., Gulliford, M. C., and Steering, C. Trial, “Point-of-care cluster randomized trial in stroke secondary prevention using electronic health records”, Stroke, vol. 45, pp. 2066-71, 2014.
A. M. Gallagher, van Staa, T. P., Murray-Thomas, T., Schoof, N., Clemens, A., Ackermann, D., and Bartels, D. B., “Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes”, BMJ Open, vol. 4, p. e003839, 2014.
T. P. van Staa, Leufkens, H., Abenhaim, L., and Cooper, C., “Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
S. Rietbrock, Olson, M., and van Staa, T. P., “The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates”, Qjm, vol. 102, pp. 35-42, 2009.
T. P. van Staa, Gulliford, M., Ng, E. S., Goldacre, B., and Smeeth, L., “Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?”, PLoS One, vol. 9, p. e106455, 2014.
T. P. van Staa, Carr, D. F., O'Meara, H., McCann, G., and Pirmohamed, M., “Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment”, Br J Clin Pharmacol, vol. 78, pp. 649-59, 2014.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
Q
A. M. Gallagher, de Vries, F., Plumb, J. M., Hass, B., Clemens, A., and van Staa, T. P., “Quality of INR control and outcomes following venous thromboembolism”, Clin Appl Thromb Hemost, vol. 18, pp. 370-8, 2012.
K. Wing, Bhaskaran, K., Pealing, L., Root, A., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., and Douglas, I., “Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study”, J Antimicrob Chemother, vol. 72, pp. 2636-2646, 2017.
R
F. de Vries, de Vries, C., Cooper, C., Leufkens, B., and van Staa, T. P., “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
Y. Li, Molter, A., White, A., Welfare, W., Palin, V., Belmonte, M., Ashcroft, D. M., Sperrin, M., and van Staa, T. P., “Relationship between prescribing of antibiotics and other medicines in primary care: a cross-sectional study”, Br J Gen Pract, vol. 69, pp. e42-e51, 2019.
R. Boggon, Lip, G. Y., Gallagher, A. M., and van Staa, T. P., “Resource utilization and outcomes in patients with atrial fibrillation: a case control study”, Appl Health Econ Health Policy, vol. 10, pp. 249-59, 2012.
K. B. Handoko, Souverein, P. C., van Staa, T. P., Meyboom, R. H., Leufkens, H. G., Egberts, T. C., and van den Bemt, P. M., “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
D. C. Braeken, Rohde, G. G., Franssen, F. M., Driessen, J. H., van Staa, T. P., Souverein, P. C., Wouters, E. F., and de Vries, F., “Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom”, Int J Chron Obstruct Pulmon Dis, vol. 12, pp. 2425-2432, 2017.
A. M. Gallagher, Smeeth, L., Seabroke, S., Leufkens, H. G., and van Staa, T. P., “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
A. Lalmohamed, de Vries, F., Bazelier, M. T., Cooper, A., van Staa, T. P., Cooper, C., and Harvey, N. C., “Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study”, Bmj, vol. 345, p. e5085, 2012.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
M. T. Bazelier, de Vries, F., Vestergaard, P., Herings, R. M., Gallagher, A. M., Leufkens, H. G., and van Staa, T. P., “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
G. W. Hugenholtz, Heerdink, E. R., van Staa, T. P., Nolen, W. A., and Egberts, A. C., “Risk of hip/femur fractures in patients using antipsychotics”, Bone, vol. 37, pp. 864-70, 2005.
D. Gibson-Smith, Klop, C., Elders, P. J., Welsing, P. M., van Schoor, N., Leufkens, H. G., Harvey, N. C., van Staa, T. P., and de Vries, F., “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
M. E. Jones, Campbell, G., Patel, D., Brunner, E., Shatapathy, C. C., Murray-Thomas, T., van Staa, T. P., and Motsko, S., “Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database”, Cardiovasc Psychiatry Neurol, vol. 2013, p. 647476, 2013.
I. J. A. de Bruin, Wyers, C. E., Souverein, P. C., van Staa, T. P., Geusens, P., van den Bergh, J. P. W., de Vries, F., and Driessen, J. H. M., “The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK”, Osteoporos Int, 2020.
E. Martin-Merino, Petersen, I., Hawley, S., Alvarez-Gutierrez, A., Khalid, S., Llorente-Garcia, A., Delmestri, A., Javaid, M. K., van Staa, T. P., Judge, A., Cooper, C., and Prieto-Alhambra, D., “Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK”, Osteoporos Int, vol. 29, pp. 467-478, 2018.
S. Bours, de Vries, F., van den Bergh, J. P. W., Lalmohamed, A., van Staa, T. P., Leufkens, H. G. M., Geusens, P. P. P., Drent, M., and Harvey, N. C., “Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort”, Osteoporos Int, vol. 27, pp. 1603-1610, 2016.
A. M. Gallagher, Setakis, E., Plumb, J. M., Clemens, A., and van Staa, T. P., “Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients”, Thromb Haemost, vol. 106, pp. 968-77, 2011.
S
J. T. Nielen, Dagnelie, P. C., Emans, P. J., Veldhorst-Janssen, N., Lalmohamed, A., van Staa, T. P., Boonen, A. E., van den Bemt, B. J., and de Vries, F., “Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1245-1252, 2016.
V. 3rd. Lo Re, Haynes, K., Ming, E. E., J. Ives, W., Horne, L. N., Fortier, K., Carbonari, D. M., Hennessy, S., Cardillo, S., Reese, P. P., Reddy, K. R., Margolis, D., Apter, A., Kimmel, S. E., Roy, J., Freeman, C. P., Razzaghi, H., Holick, C. N., Esposito, D. B., van Staa, T. P., Bhullar, H., and Strom, B. L., “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.
R. Y. van der Velde, Wyers, C. E., Curtis, E. M., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., van Staa, T. P., and Harvey, N. C., “Secular trends in fracture incidence in the UK between 1990 and 2012”, Osteoporos Int, vol. 27, pp. 3197-3206, 2016.
F. de Vries, van Staa, T. P., Bracke, M. S., Cooper, C., Leufkens, H. G., and Lammers, J. W., “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
T. P. van Staa, Geusens, P., Pols, H. A., de Laet, C., Leufkens, H. G., and Cooper, C., “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
M. T. Bazelier, van Staa, T. P., Uitdehaag, B. M., Cooper, C., Leufkens, H. G., Vestergaard, P., Bentzen, J., and de Vries, F., “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
[Page last reviewed 4 February 2021]